Literature DB >> 16186590

Is there a role for routine p53 testing in colorectal cancer?

Paulo M Hoff.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16186590     DOI： 10.1200/JCO.2005.07.021

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  7 in total

1.  Targeting tumors using nanoparticle platforms: a phase I study of a systemically administered gene therapy system.

Authors:  Christopher Larson; Natalie Mendez; Tony Reid
Journal:  Mol Ther       Date:  2013-05       Impact factor: 11.454

2.  Frequent concomitant inactivation of miR-34a and miR-34b/c by CpG methylation in colorectal, pancreatic, mammary, ovarian, urothelial, and renal cell carcinomas and soft tissue sarcomas.

Authors:  Markus Vogt; Johanna Munding; Martha Grüner; Sven-Thorsten Liffers; Berlinda Verdoodt; Jennifer Hauk; Lars Steinstraesser; Andrea Tannapfel; Heiko Hermeking
Journal:  Virchows Arch       Date:  2011-01-12       Impact factor: 4.064

Review 3.  Clinical outcomes and correlates of TP53 mutations and cancer.

Authors:  Ana I Robles; Curtis C Harris
Journal:  Cold Spring Harb Perspect Biol       Date:  2010-03       Impact factor: 10.005

4.  p53 protein accumulation as a prognostic marker in sporadic colorectal cancer.

Authors:  Yuan-Tzu Lan; Shih-Ching Chang; Anna Fen-Yau Li; Tzu-Chen Lin; Wei-Shone Chen; Jeng-Kai Jiang; Shung-Haur Yang; Huann-Sheng Wang; Jen-Kou Lin
Journal:  Int J Colorectal Dis       Date:  2006-10-05       Impact factor: 2.796

5.  Changes in the status of p53 affect drug sensitivity to thymidylate synthase (TS) inhibitors by altering TS levels.

Authors:  E Giovannetti; H H J Backus; D Wouters; C G Ferreira; V M M van Houten; R H Brakenhoff; M-F Poupon; A Azzarello; H M Pinedo; G J Peters
Journal:  Br J Cancer       Date:  2007-03-12       Impact factor: 7.640

6.  Clinical next generation sequencing to identify actionable aberrations in a phase I program.

Authors:  Genevieve M Boland; Sarina A Piha-Paul; Vivek Subbiah; Mark Routbort; Shelley M Herbrich; Keith Baggerly; Keyur P Patel; Lauren Brusco; Chacha Horombe; Aung Naing; Siqing Fu; David S Hong; Filip Janku; Amber Johnson; Russell Broaddus; Raja Luthra; Kenna Shaw; John Mendelsohn; Gordon B Mills; Funda Meric-Bernstam
Journal:  Oncotarget       Date:  2015-08-21

7.  PIK3CA and TP53 mutations predict overall survival of stage II/III colorectal cancer patients.

Authors:  A-Jian Li; Hua-Guang Li; Er-Jiang Tang; Wei Wu; Ying Chen; Hui-Hong Jiang; Mou-Bin Lin; Lu Yin
Journal:  World J Gastroenterol       Date:  2018-02-07       Impact factor: 5.742
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.